• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1999 年至 2014 年美国难治性高血压的患病率。

Prevalence of refractory hypertension in the United States from 1999 to 2014.

机构信息

Department of Internal Medicine.

Center for Clinical Research.

出版信息

J Hypertens. 2019 Sep;37(9):1797-1804. doi: 10.1097/HJH.0000000000002103.

DOI:10.1097/HJH.0000000000002103
PMID:31058798
Abstract

OBJECTIVES

Refractory hypertension has been defined as uncontrolled blood pressure (at or above 140/90 mmHg) when on five or more classes of antihypertensive medication, inclusive of a diuretic. Because unbiased estimates of the prevalence of refractory hypertension in the United States are lacking, we aim to provide such estimates using data from the National Health and Nutrition Examination Surveys (NHANES).

METHODS

Refractory hypertension was assessed across multiple NHANES cycles using the aforementioned definition. Eight cycles of NHANES surveys (1999-2014) representing 41 552 patients are the subject of this study. Prevalence of refractory hypertension across these surveys was estimated in the drug-treated hypertensive population after adjusting for the complex survey design and standardizing for age.

RESULTS

Across all surveys, refractory hypertension prevalence was 0.6% [95% confidence interval (CI) (0.5, 0.7)] amongst drug-treated hypertensive adults; 6.2% [95% CI (5.1, 7.6)] of individuals with treatment-resistant hypertension actually had refractory hypertension. Although the prevalence of refractory hypertension ranged from 0.3% [95% CI (0.1, 1.0)] to 0.9% [95% CI (0.6, 1.2)] over the eight cycles considered, there was no significant trend in prevalence over time. Refractory hypertension prevalence amongst those prescribed five or more drugs was 34.5% [95% CI (27.9, 41.9)]. Refractory hypertension was associated with advancing age, lower household income, black race, and also chronic kidney disease, albuminuria, diabetes, prior stroke, and coronary heart disease.

CONCLUSIONS

We provided the first nationally representative estimate of refractory hypertension prevalence in US adults.

摘要

目的

难治性高血压被定义为在服用五种或更多种降压药物(包括利尿剂)时血压仍无法控制(在 140/90mmHg 以上)。由于美国缺乏难治性高血压的无偏估计值,我们旨在使用国家健康和营养检查调查(NHANES)的数据提供此类估计值。

方法

使用上述定义,在多个 NHANES 周期中评估难治性高血压。这项研究的对象是 8 个 NHANES 调查周期(1999-2014 年),共代表 41552 名患者。在对复杂的调查设计进行调整并根据年龄进行标准化后,在药物治疗的高血压患者中估计了这些调查中难治性高血压的患病率。

结果

在所有调查中,药物治疗的高血压成年患者中难治性高血压的患病率为 0.6%(95%置信区间(CI)(0.5,0.7));实际上有难治性高血压的治疗抵抗性高血压患者中,有 6.2%(95%CI(5.1,7.6))。尽管考虑到的 8 个周期中难治性高血压的患病率从 0.3%(95%CI(0.1,1.0))到 0.9%(95%CI(0.6,1.2))不等,但在时间上没有明显的趋势。服用五种或更多种药物的患者中难治性高血压的患病率为 34.5%(95%CI(27.9,41.9))。难治性高血压与年龄增长、家庭收入较低、黑种人以及慢性肾脏病、白蛋白尿、糖尿病、既往中风和冠心病有关。

结论

我们提供了美国成年人难治性高血压患病率的首次全国代表性估计值。

相似文献

1
Prevalence of refractory hypertension in the United States from 1999 to 2014.1999 年至 2014 年美国难治性高血压的患病率。
J Hypertens. 2019 Sep;37(9):1797-1804. doi: 10.1097/HJH.0000000000002103.
2
Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline.根据 2017 年高血压指南,美国明显治疗抵抗性高血压的流行情况。
Mayo Clin Proc. 2019 May;94(5):776-782. doi: 10.1016/j.mayocp.2018.12.033.
3
Trends in Antihypertensive Medication Use Among Individuals With a History of Stroke and Hypertension, 2005 to 2016.2005 年至 2016 年期间有中风和高血压病史的个体中抗高血压药物使用的趋势。
JAMA Neurol. 2020 Nov 1;77(11):1382-1389. doi: 10.1001/jamaneurol.2020.2499.
4
Antihypertensive drug use and blood pressure control among stroke survivors in the United States: NHANES 2003-2014.美国脑卒中幸存者的抗高血压药物使用与血压控制情况:NHANES 2003-2014 年。
J Clin Hypertens (Greenwich). 2019 Jun;21(6):766-773. doi: 10.1111/jch.13553. Epub 2019 May 17.
5
Prevalence of resistant hypertension in the United States, 2003-2008.美国 2003-2008 年耐药性高血压的流行情况。
Hypertension. 2011 Jun;57(6):1076-80. doi: 10.1161/HYPERTENSIONAHA.111.170308. Epub 2011 Apr 18.
6
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.难治性高血压:在一个大型基于人群的队列中确定患病率、风险因素和合并症。
Hypertension. 2014 Mar;63(3):451-8. doi: 10.1161/HYPERTENSIONAHA.113.02026. Epub 2013 Dec 9.
7
Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.难治性和顽固性高血压:抗高血压治疗抵抗与治疗失败
Can J Cardiol. 2016 May;32(5):603-6. doi: 10.1016/j.cjca.2015.06.033. Epub 2015 Jul 8.
8
US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.美国高血压的患病率、知晓率、治疗率和控制率趋势,1988-2008 年。
JAMA. 2010 May 26;303(20):2043-50. doi: 10.1001/jama.2010.650.
9
Vital signs: prevalence, treatment, and control of hypertension--United States, 1999-2002 and 2005-2008.生命体征:1999-2002 年和 2005-2008 年美国高血压的流行率、治疗和控制情况。
MMWR Morb Mortal Wkly Rep. 2011 Feb 4;60(4):103-8.
10
Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010.美国高血压成年人降压药物使用和血压控制趋势:2001 至 2010 年国家健康和营养调查。
Circulation. 2012 Oct 23;126(17):2105-14. doi: 10.1161/CIRCULATIONAHA.112.096156.

引用本文的文献

1
Trends in Blood Pressure Control in US Adult CKD Patients from 1999 to 2018.1999年至2018年美国成年慢性肾脏病患者的血压控制趋势
Int J Med Sci. 2025 Jan 13;22(3):696-707. doi: 10.7150/ijms.103107. eCollection 2025.
2
A Review of the Risk Factors and Management of Refractory Hypertension: The Role of Carotid Sinus Stimulation and Renal Nerve Denervation.难治性高血压的危险因素及管理综述:颈动脉窦刺激和肾神经去支配的作用
J Community Hosp Intern Med Perspect. 2024 Jul 2;14(4):18-24. doi: 10.55729/2000-9666.1364. eCollection 2024.
3
The Global Burden of Resistant Hypertension and Potential Treatment Options.
难治性高血压的全球负担及潜在治疗方案
Eur Cardiol. 2024 Jun 19;19:e07. doi: 10.15420/ecr.2023.51. eCollection 2024.
4
Resistant Hypertension: Disease Burden and Emerging Treatment Options.耐药性高血压:疾病负担与新兴治疗选择。
Curr Hypertens Rep. 2024 May;26(5):183-199. doi: 10.1007/s11906-023-01282-0. Epub 2024 Feb 16.
5
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.非奈利酮用于2型糖尿病合并慢性肾脏病的黑人患者:FIDELIO-DKD和FIGARO-DKD试验汇总的事后分析
Kidney Med. 2023 Sep 28;5(12):100730. doi: 10.1016/j.xkme.2023.100730. eCollection 2023 Dec.
6
Associations of blood lead, cadmium, and mercury with resistant hypertension among adults in NHANES, 1999-2018.血液铅、镉和汞与 1999-2018 年 NHANES 中成年人耐药性高血压的关联。
Environ Health Prev Med. 2023;28:66. doi: 10.1265/ehpm.23-00151.
7
Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC.利用当代指南对明显耐药性高血压患者进行特征描述:来自 CV-QUIC 的见解。
Hypertension. 2023 Sep;80(9):1845-1855. doi: 10.1161/HYPERTENSIONAHA.123.20894. Epub 2023 Jun 26.
8
An Update on Refractory Hypertension.难治性高血压的最新进展
Curr Hypertens Rep. 2022 Jul;24(7):225-234. doi: 10.1007/s11906-022-01185-6. Epub 2022 Apr 6.
9
Current status of adherence interventions in hypertension management in Asian countries: A report from the HOPE Asia Network.亚洲国家高血压管理中依从性干预措施的现状:希望亚洲网络的报告。
J Clin Hypertens (Greenwich). 2020 Dec 17;23(3):584-94. doi: 10.1111/jch.14104.
10
Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets.慢性肾脏病(CKD)中的高血压:诊断、分类和治疗靶点。
Am J Hypertens. 2021 Apr 20;34(4):318-326. doi: 10.1093/ajh/hpaa209.